During a Case-Based Roundtable® event, Ajay Nooka, MD, MPH, discussed adverse events related to talquetamab for multiple ...

Tocilizumab -- an interleukin (IL)-6 receptor inhibitor -- was approved by the FDA in 2017 for the treatment of severe or ...

An unusual placebo effect in Aligos Therapeutics’ Phase IIa trial is driving shareholder skepticism for its metabolic ...

SAINT study is currently investigating intravenous trabectedin plus ipilimumab and nivolumab in the first line for advanced ...

After missing primary endpoints in relapsing forms of MS, tolebrutinib has proved its efficacy in secondary progressive MS ...

In an interview with Targeted Oncology, Mark R. Litzow, MD, discussed the incorporation of Immunotherapy into upfront acute ...

CFT1946 Is Well-Tolerated at All Dose Levels; No Dose-Limiting Toxicities CFT1946 Achieves Dose Proportional Pharmacokinetic Exposure; Successfully Degrades BRAF V600 Mutant Protein Early Evidence of ...

Two Types. Confocal microscopy reveals α-synuclein (green) and lipids (red) in three adjacent inclusions (left and right). The white arrows point to Type I inclusions loaded with lipids. Blue ...

NKT2152, a novel HIF2a inhibitor, demonstrates significant efficacy in patients with advanced clear cell renal cell carcinoma ...

Garlic is the most toxic of that group. “It’s one of the most commonly not-noticed toxicities because people will not think about the fact that most food has garlic or onion in it,” says Diana Watkins ...